CA2081462A1 - Five-membered ring alkanoic acid leukotriene antagonists - Google Patents

Five-membered ring alkanoic acid leukotriene antagonists

Info

Publication number
CA2081462A1
CA2081462A1 CA002081462A CA2081462A CA2081462A1 CA 2081462 A1 CA2081462 A1 CA 2081462A1 CA 002081462 A CA002081462 A CA 002081462A CA 2081462 A CA2081462 A CA 2081462A CA 2081462 A1 CA2081462 A1 CA 2081462A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
phenyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002081462A
Other languages
English (en)
French (fr)
Inventor
James S. Frazee
John G. Gleason
Ralph F. Hall
Irene N. Uzinskas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2081462A1 publication Critical patent/CA2081462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002081462A 1990-05-01 1991-04-26 Five-membered ring alkanoic acid leukotriene antagonists Abandoned CA2081462A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51712090A 1990-05-01 1990-05-01
US517,120 1990-05-01
PCT/US1991/002884 WO1991016889A1 (en) 1990-05-01 1991-04-26 Five-membered ring alkanoic acid leukotriene antagonists

Publications (1)

Publication Number Publication Date
CA2081462A1 true CA2081462A1 (en) 1991-11-02

Family

ID=24058448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002081462A Abandoned CA2081462A1 (en) 1990-05-01 1991-04-26 Five-membered ring alkanoic acid leukotriene antagonists

Country Status (5)

Country Link
EP (1) EP0528957A4 (ja)
JP (1) JPH05507082A (ja)
AU (1) AU7902991A (ja)
CA (1) CA2081462A1 (ja)
WO (1) WO1991016889A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
EP1486493A4 (en) * 2002-03-19 2007-04-04 Mitsubishi Chem Corp 3-HYDROXY-3- (2-THIENYL) PROPIONIC ACID AMID COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR PRODUCING A 3-AMINO-1- (2-THIENYL) -1-PROPANOL COMPOUND THEREFOR
DE10212301A1 (de) * 2002-03-20 2003-10-02 Bayer Ag Verfahren zur Herstellung von Aryl-aminopropanolen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609744A (en) * 1983-04-21 1986-09-02 Merck Frosst Canada Inc. 4-oxo-benzopyran carboxylic acids
US4730005A (en) * 1984-01-19 1988-03-08 Smithkline Beckman Corporation Leukotriene antagonist
EP0202759B1 (en) * 1985-04-19 1990-06-20 Smithkline Beecham Corporation Leukotriene antagonists
ZA896260B (en) * 1988-08-22 1990-05-30 Merrell Dow Pharma Phenylalkylthiophenes and related compounds
US4954513A (en) * 1988-12-23 1990-09-04 Smithkline Beecham Corporation Leukotriene antagonists

Also Published As

Publication number Publication date
WO1991016889A1 (en) 1991-11-14
JPH05507082A (ja) 1993-10-14
AU7902991A (en) 1991-11-27
EP0528957A1 (en) 1993-03-03
EP0528957A4 (en) 1993-05-05

Similar Documents

Publication Publication Date Title
JP3341019B2 (ja) 選択的ロイコトリエンｂ▲４▼拮抗剤活性を示す置換された単環式アリール化合物
EP0219308B1 (en) 2-substituted quinolines
CA1334200C (en) Leukotriene antagonists
CA2081462A1 (en) Five-membered ring alkanoic acid leukotriene antagonists
JPH02124869A (ja) ロイコトリエン拮抗剤のエステルプロドラッグ
US4996214A (en) Quinolinyl substituted phenyl/thioalkanoic acid substituted propionic acids and leucotriene antagonist use thereof
GB2190377A (en) Phenyldithiaalkanedioic acids as leukotriene antagonists
EP0296731B1 (en) Leukotriene antagonists
AU610528B2 (en) Leukotriene antagonists
EP0548291A1 (en) Pyridylthio or pyridyloxy alkanoic acids
CA2005349A1 (en) Leukotriene antagonists
US5143931A (en) Leukotriene antagonists containing tetrazolyl groups
JPS6270351A (ja) 置換ジ−ｔ−ブチルフエノ−ル類
AU7769491A (en) 3-naphthyl-3-carboxyalkylthio or oxy substituted alkanoic acid leukotriene antagonists
IE902588A1 (en) Substituted quinolines
CA1314654C (en) Leukotriene antagonists
EP0403249A1 (en) Leukotriene antagonists
JPH02237988A (ja) イソオキサゾロピリジン系メバロノラクトン類
JP2520416B2 (ja) ω−〔〔〔５−（置換ベンジルチオ）チアジアゾ−ル−２−イル〕チオメチル〕フエノキシ〕アルキルカルボン酸
EP0532674A1 (en) Leukotriene antagonists
IE912180A1 (en) Chemical compounds
IE60494B1 (en) Leukotriene antagonists

Legal Events

Date Code Title Description
FZDE Dead